Healthcare Venture Partners

MyOme is a biotechnology company that specializes in gene analytics technology aimed at understanding the impact of DNA on health and well-being. Through advanced genome sequencing, MyOme provides insights into a range of common and rare diseases, including coronary heart disease. The company's innovative approach allows it to estimate the risk of various multi-factorial medical conditions, empowering families to take proactive measures to reduce the likelihood of diseases being inherited across generations. MyOme's data is designed to be secure, portable, and reusable throughout an individual's life, ensuring that valuable genetic information can be accessed and utilized effectively over time.

Paige is a company founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializing in computational pathology products aimed at enhancing diagnostic precision and treatment decision-making for cancer patients. The company has developed a platform that employs advanced deep learning algorithms, including convolutional and recurrent neural networks, to enable rapid diagnostic stratification and cancer detection, particularly for breast, prostate, and other major cancer types. This innovative technology is designed to transform the workflow of pathologists, providing them with insights that lead to more accurate diagnoses while minimizing the burden on IT systems and ensuring patient safety and data privacy. Paige is recognized as the first organization to receive FDA breakthrough designation for its computational pathology products.

Paige is a company founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializing in computational pathology products aimed at enhancing diagnostic precision and treatment decision-making for cancer patients. The company has developed a platform that employs advanced deep learning algorithms, including convolutional and recurrent neural networks, to enable rapid diagnostic stratification and cancer detection, particularly for breast, prostate, and other major cancer types. This innovative technology is designed to transform the workflow of pathologists, providing them with insights that lead to more accurate diagnoses while minimizing the burden on IT systems and ensuring patient safety and data privacy. Paige is recognized as the first organization to receive FDA breakthrough designation for its computational pathology products.